Trending...
- The Squires Group Becomes a Workday Partner
- How AI Exposed Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's® Patented Netverse®, App-less Solution
- SQUARESIGNS Featured in Inc.5000 List Again
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella.
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Pieris will issue shares of Pieris common stock to pre-merger Palvella stockholders as merger consideration in exchange for the cancellation of shares of capital stock of Palvella, and Palvella will become a wholly-owned subsidiary of Pieris. However, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company and pre-merger Palvella stockholders are expected to own approximately 82% of the combined company, subject to adjustments and additional shares issued in a concurrent private placement. Pieris pre-merger stockholders will also be issued a contingent value right (CVR) representing the right to receive payments from, among other sources, proceeds received by the combined company, if any, under Pieris' existing partnership agreements with Pfizer and Boston Pharmaceuticals.
More on Wisconsin Eagle
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
- AureaVault Launches U.S.-Licensed Cryptocurrency Exchange with Enhanced Security Features
- IOTAP Named to 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
- Lineus Medical and Venture Medical Sign New Zealand Distribution Agreement
The transaction agreement unreasonably limits competing transactions by Pieris as it imposes a significant penalty if Pieris accepts a competing bid. Pieris insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Pieris' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Pieris common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pieris-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
SOURCE Ademi LLP
Filed Under: Business
0 Comments
Latest on Wisconsin Eagle
- Shincheonji Tanzania Church Holds Revelation Bible Exam with Local Pastors and Believers
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- Tavern Team Launches Full Bar Solution for Wisconsin Venues Ahead of 2026 Liquor Licensing Law
- TRA Earns Brandon Hall Group Bronze Award for Innovation in Learning & Development
- "When The Call Hits Home" Explores the Evolving World of Law Enforcement and Mental Health
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- From Vernon Hills to Mensa Before Kindergarten
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality
- Allen Field to Showcase Sustainable Paper Handle Applicator at PACK EXPO Las Vegas 2025
- Laughter, Magic & Mayhem Take Over Las Vegas At Two Hot Locations! Delirious Comedy Club & House of Magic Bring Nonstop Entertainment
- 500% Increase in Revenue for Q2 with Acquisition Plans Including UK Telecom 3D Design/Modeling Company for Global AI Drone & Quantum Computing Leader
- K2 Integrity and Rafidain Bank Launch Strategic Partnership to Strengthen Financial Integrity
- Anern's 2025 Global Energy Journey: Expanding Clean Energy Across Four Continents
- Joint Venture for Expansion Into Asset-Backed Real Estate; $100 Million Initiative via Offering of Shares at Over $4 for Digital Assets: $OFAL
- Mrs. Field's Closet Expands to Minot North High School